Literature DB >> 26363121

Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.

Shanthi Kanthala1, Christopher P Mill2, David J Riese3, Mihir Jaiswal4, Seetharama Jois5.   

Abstract

Overexpression of human epidermal growth factor receptor 2 (HER2/ErbB2/Neu) results in ligand independent activation of kinase signaling and is found in about 30% of human breast cancers, and is correlated with a more aggressive tumor phenotype. The HER2 extracellular domain (ECD) consists of four domains - I, II, III and IV. Although the role of each domain in the dimerization and activation of the receptor has been extensively studied, the role of domain IV (DIV) is not clearly understood yet. In our previous studies, we reported peptidomimetic molecules inhibit HER2:HER3 heterodimerization. In order to study the binding interactions of peptidomimetics with HER2 DIV in detail, properly folded recombinant HER2 protein in pure form is important. We have expressed and purified HER2 ECD and DIV proteins in the Drosophila melanogaster Schneider2 (S2) cell line. Using the commercial Drosophila expression system (DES), we transfected S2 cells with plasmids designed to direct the expression of secreted recombinant HER2 ECD and DIV proteins. The secreted proteins were purified from the conditioned medium by filtration, ultrafiltration, dialysis and nickel affinity chromatography techniques. The purified HER2 proteins were then analyzed using Western blot, mass spectrometry and circular dichroism (CD) spectroscopy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disulfide loops; Human epidermal growth factor receptor 2; Mass spectrometry; Protein secretion; Protein sequencing; S2 insect cell lines

Mesh:

Substances:

Year:  2015        PMID: 26363121      PMCID: PMC4785095          DOI: 10.1016/j.pep.2015.09.001

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  35 in total

1.  Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.

Authors:  Sashikanth Banappagari; Miriam Corti; Seth Pincus; Seetharama Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2012-06-26

2.  HER2 inhibition: from discovery to clinical practice.

Authors:  Jenny C Chang
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

3.  Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.

Authors:  Sashikanth Banappagari; Sharon Ronald; Seetharama D Satyanarayanajois
Journal:  Medchemcomm       Date:  2011-01-01       Impact factor: 3.597

4.  [Soluble expression and characterization of disulfide bond-rich subdomains of membrane protein p185 in Escherichia coli].

Authors:  Liang-Wei Li; Hai-Bo Liu; Si-Yi Hu; Dun Liang; Lian-Sheng Cheng; Jing Liu
Journal:  Sheng Wu Gong Cheng Xue Bao       Date:  2005-07

5.  Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding.

Authors:  M L Saxon; D C Lee
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

6.  Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.

Authors:  Chafen Lu; Li-Zhi Mi; Michael J Grey; Jieqing Zhu; Elizabeth Graef; Shigeyuki Yokoyama; Timothy A Springer
Journal:  Mol Cell Biol       Date:  2010-09-13       Impact factor: 4.272

7.  Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.

Authors:  Shanthi Kanthala; Ted Gauthier; Seetharama Satyanarayanajois
Journal:  Biopolymers       Date:  2014-06       Impact factor: 2.505

8.  Same fold with different mobility: backbone dynamics of small protease inhibitors from the desert locust, Schistocerca gregaria.

Authors:  Borbála Szenthe; Zoltán Gáspári; Attila Nagy; András Perczel; László Gráf
Journal:  Biochemistry       Date:  2004-03-30       Impact factor: 3.162

Review 9.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  Improving heterologous protein expression in transfected Drosophila S2 cells as assessed by EGFP expression.

Authors:  Mariza G Santos; Soraia A C Jorge; Karl Brillet; Carlos A Pereira
Journal:  Cytotechnology       Date:  2007-03-20       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.